• FGFR-driven diseases go beyond the diagnosis,
    QED is committed to finding solutions

  • FGFR-driven diseases go beyond the diagnosis,
    QED is committed to finding solutions

  • FGFR-driven diseases go beyond the diagnosis,
    QED is committed to finding solutions

  • FGFR-driven diseases go beyond the diagnosis,
    QED is committed to finding solutions

1234
Cholangiocarcinoma:

Investigating FGFR-targeted therapy

Urothelial Carcinoma:

Discover more about
urinary tract and bladder cancer

Achondroplasia:

Learn about PROPEL and PROPEL 2

Latest Press Releases

12.01.2020

BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma

08.11.2020

BridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio

07.28.2020

Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics Announce Dosing of First Patient in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent Glioblastoma

Contact Us

75 Federal Street
San Francisco, CA 94107

1-877-280-5655

Maps were disabled by the visitor on this site.